IKT
Inhibikase·NASDAQ
--
--(--)
--
--(--)
IKT fundamentals
During Q3 2025, Inhibikase (IKT) reported revenue of --, a YoY change of 0.00%. Net income was -11.93M, a YoY change of -106.48%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2019 | Q2,2019 | Q3,2019 | Q4,2019 | Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Jan 1, 2019 | Apr 1, 2019 | Jul 1, 2019 | Oct 1, 2019 | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Mar 31, 2019 | Jun 30, 2019 | Sep 30, 2019 | Dec 31, 2019 | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 591.10K -- | 166.93K -- | 124.43K -- | 240.28K -- | 270.79K -54.19% | 219.59K +31.54% | 37.68K -69.72% | 170.42K -29.07% | 1.41M +419.66% | 1.36M +520.73% | 328.46K +771.71% | 1.94K -98.86% | 46.03K -96.73% | 6.55K -99.52% | 7.29K -97.78% | 63.57K +3169.86% | 64.52K +40.17% | 116.41K +1676.71% | 79.57K +991.33% | 1 -100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | 591.10K -- | 166.93K -- | 124.43K -- | 240.28K -- | 270.79K -54.19% | 219.59K +31.54% | 37.68K -69.72% | 170.42K -29.07% | 1.41M +419.66% | 1.36M +520.73% | 328.46K +771.71% | 1.94K -98.86% | 46.03K -96.73% | 6.55K -99.52% | 7.29K -97.78% | 63.57K +3169.86% | 64.52K +40.17% | 116.41K +1676.71% | 79.57K +991.33% | 1 -100.00% | -- -- | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | 591.10K -- | 166.93K -- | 124.43K -- | -882.46K -- | 270.79K -54.19% | 219.59K +31.54% | 37.68K -69.72% | -528.05K +40.16% | 1.41M +419.66% | 1.36M +520.73% | 328.46K +771.71% | -3.10M -486.81% | 46.03K -96.73% | 6.55K -99.52% | 7.29K -97.78% | -59.87K +98.07% | 64.52K +40.17% | 116.41K +1676.71% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Operating Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | 0 -- | 1.16M -- | 358.42K -- | 492.83K -- | 2.02M -- |
Operating Expenses | 2.32M -- | 2.51M -- | 1.33M -- | 662.54K -- | 810.80K -65.11% | 633.51K -74.72% | 701.39K -47.23% | 1.37M +106.97% | 4.03M +397.34% | 3.99M +530.05% | 4.80M +584.28% | 5.04M +267.79% | 4.69M +16.22% | 4.65M +16.41% | 4.52M -5.82% | 4.40M -12.79% | 4.78M +1.98% | 6.32M +35.99% | 4.85M +7.26% | 4.40M +0.11% | 4.78M +0.06% | 5.05M -20.07% | 5.83M +20.19% | 12.93M +193.60% | 15.76M +229.60% | 11.19M +121.57% | 13.26M +127.56% | 53.14M -- |
Selling, General and Administrative Expenses | 767.99K -- | 2.03M -- | 1.07M -- | 394.62K -- | 527.69K -31.29% | 370.33K -81.77% | 580.82K -45.92% | 1.14M +189.98% | 1.60M +203.32% | 1.61M +334.47% | 1.64M +183.21% | 1.65M +44.47% | 1.67M +4.31% | 1.66M +3.44% | 1.54M -6.46% | 1.34M -18.68% | 1.93M +15.32% | 1.78M +7.14% | 1.62M +5.47% | 1.40M +4.18% | 2.03M +5.49% | 1.97M +10.74% | 1.64M +0.91% | 5.74M +309.48% | 5.25M +158.45% | 5.92M +199.78% | 5.61M +242.67% | 22.52M -- |
Research and Development Expenses | 1.56M -- | 474.05K -- | 254.97K -- | 267.92K -- | 283.11K -81.80% | 263.18K -44.48% | 120.57K -52.71% | 226.94K -15.29% | 2.43M +758.97% | 2.38M +805.27% | 3.15M +2516.39% | 3.39M +1393.87% | 3.02M +24.06% | 2.98M +25.17% | 2.98M -5.48% | 3.05M -9.91% | 2.85M -5.40% | 4.54M +52.09% | 3.23M +8.18% | 3.00M -1.68% | 2.75M -3.60% | 3.08M -32.19% | 4.19M +29.90% | 7.19M +139.55% | 10.51M +282.13% | 5.27M +71.37% | 7.65M +82.58% | 30.63M -- |
Other Operating Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -1.73M -- | -2.34M -- | -1.20M -- | -422.26K -- | -540.01K +68.83% | -413.92K +82.30% | -663.71K +44.90% | -1.20M -184.38% | -2.63M -386.15% | -2.63M -534.99% | -4.47M -573.64% | -5.04M -319.83% | -4.64M -76.77% | -4.64M -76.53% | -4.51M -0.94% | -4.33M +14.01% | -4.71M -1.60% | -6.20M -33.67% | -4.77M -5.67% | -4.40M -1.58% | -4.78M -1.43% | -5.05M +18.57% | -5.83M -22.20% | -12.93M -193.60% | -14.60M -205.25% | -10.83M -114.48% | -12.77M -119.11% | -51.13M -- |
Non-Operating Income (Loss) | -3.67K -- | -5.61K -- | -7.81K -- | -7.75K -- | -7.42K -102.32% | -7.95K -41.78% | -6.89K +11.80% | -7.14K +7.85% | -11.80K -58.88% | -7.81K +1.72% | -157 +97.72% | -158 +97.79% | -5 +99.96% | -- -- | 18.54K +11906.37% | 55.92K +35493.67% | 237.17K +4743520.00% | 424.44K -- | 173.68K +836.97% | 225.63K +303.47% | 132.72K -44.04% | 90.93K -78.58% | 49.41K -71.55% | 796.12K +252.85% | 919.27K +592.61% | 916.75K +908.23% | 838.09K +1596.20% | 3.47M -- |
Net Interest Expense | 3.67K -- | 5.61K -- | 7.81K -- | 7.75K -- | 7.42K +102.32% | 7.95K +41.78% | 6.89K -11.80% | 7.14K -7.85% | 11.80K +58.88% | 7.81K -1.72% | 157 -97.72% | 158 -97.79% | 5 -99.96% | -- -- | -18.54K -11906.37% | -55.92K -35493.67% | -237.17K -4743520.00% | -424.44K -- | -173.68K -836.97% | -225.63K -303.47% | -132.72K +44.04% | -90.93K +78.58% | -49.41K +71.55% | -796.12K -252.85% | -919.27K -592.61% | -916.75K -908.23% | -838.09K -1596.20% | -3.47M -- |
Interest Expense | 3.67K -- | 5.61K -- | 7.81K -- | 7.75K -- | 7.42K +102.32% | 7.95K +41.78% | 6.89K -11.80% | 7.14K -7.85% | 11.80K +58.88% | 7.81K -1.72% | 157 -97.72% | 158 -97.79% | 5 -99.96% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 18.54K -- | 55.92K -- | 237.17K -- | 424.44K -- | 173.68K +836.97% | 225.63K +303.47% | 132.72K -44.04% | 90.93K -78.58% | 49.41K -71.55% | 796.12K +252.85% | 919.27K +592.61% | 916.75K +908.23% | 838.09K +1596.20% | 3.47M -- |
Pretax Income From Continuing Operations | -1.74M -- | -2.34M -- | -1.21M -- | -430.01K -- | -547.44K +68.47% | -421.87K +82.00% | -670.60K +44.69% | -1.21M -180.92% | -2.64M -381.71% | -2.64M -524.88% | -4.47M -566.75% | -5.04M -317.36% | -4.64M -75.98% | -4.64M -76.01% | -4.49M -0.52% | -4.28M +15.13% | -4.48M +3.51% | -5.78M -24.53% | -4.60M -2.24% | -4.18M +2.36% | -4.65M -3.84% | -4.96M +14.16% | -5.78M -25.74% | -12.13M -190.40% | -13.68M -194.19% | -9.92M -99.93% | -11.93M -106.48% | -47.66M -- |
Income Tax Expense | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -1.74M -- | -2.34M -- | -1.21M -- | -430.01K -- | -547.44K +68.47% | -421.87K +82.00% | -670.60K +44.69% | -1.21M -180.92% | -2.64M -381.71% | -2.64M -524.88% | -4.47M -566.75% | -5.04M -317.36% | -4.64M -75.98% | -4.64M -76.01% | -4.49M -0.52% | -4.28M +15.13% | -4.48M +3.51% | -5.78M -24.53% | -4.60M -2.24% | -4.18M +2.36% | -4.65M -3.84% | -4.96M +14.16% | -5.78M -25.74% | -12.13M -190.40% | -13.68M -194.19% | -9.92M -99.93% | -11.93M -106.48% | -47.66M -- |
Net Income Attributable to Owners of the Company | -1.74M -- | -2.34M -- | -1.21M -- | -430.01K -- | -547.44K +68.47% | -421.87K +82.00% | -670.60K +44.69% | -1.21M -180.92% | -2.64M -381.71% | -2.64M -524.88% | -4.47M -566.75% | -5.04M -317.36% | -4.64M -75.98% | -4.64M -76.01% | -4.49M -0.52% | -4.28M +15.13% | -4.48M +3.51% | -5.78M -24.53% | -4.60M -2.24% | -4.18M +2.36% | -4.65M -3.84% | -4.96M +14.16% | -5.78M -25.74% | -12.13M -190.40% | -13.68M -194.19% | -9.92M -99.93% | -11.93M -106.48% | -47.66M -- |
Net Income Attributable to Common Stockholders | -1.74M -- | -2.34M -- | -1.21M -- | -430.01K -- | -547.44K +68.47% | -421.87K +82.00% | -670.60K +44.69% | -1.21M -180.92% | -2.64M -381.71% | -2.64M -524.88% | -4.47M -566.75% | -5.04M -317.36% | -4.64M -75.98% | -4.64M -76.01% | -4.49M -0.52% | -4.28M +15.13% | -4.48M +3.51% | -5.78M -24.53% | -4.60M -2.24% | -4.18M +2.36% | -4.65M -3.84% | -4.96M +14.16% | -5.78M -25.74% | -12.13M -190.40% | -13.68M -194.19% | -9.92M -99.93% | -11.93M -106.48% | -47.66M -- |
Other Comprehensive Income | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 26.83K -- | 77.89K -- | 61.10K -- | -167.54K -- | 1.57K -94.14% | 1.02K -98.69% | -2.68K -104.38% | 776 +100.46% | 2.78K +76.83% | -39.00K -3923.73% | 36.28K +1455.29% | -1.98K -354.77% | -1.25K -144.82% | -5.94K -- |
Total Comprehensive Income | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -4.47M -- | -5.04M -- | -4.64M -- | -4.64M -- | -4.47M +0.08% | -4.20M +16.67% | -4.42M +4.83% | -5.95M -28.14% | -4.59M -2.82% | -4.18M +0.58% | -4.65M -5.34% | -4.96M +16.60% | -5.78M -25.72% | -12.17M -191.40% | -13.64M -193.24% | -9.92M -100.00% | -11.93M -106.60% | -47.66M -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -5.72M -- | -- -- | -- -- | -- -- | -2.85M +50.24% | -- -- | -- -- | -4.47M -- | -5.04M -77.03% | -4.64M -- | -4.64M -- | -4.47M +0.08% | -4.20M +16.67% | -4.42M +4.83% | -5.95M -28.14% | -4.59M -2.82% | -4.18M +0.58% | -4.65M -5.34% | -4.96M +16.60% | -5.78M -25.72% | -12.17M -191.40% | -13.64M -193.24% | -9.92M -100.00% | -11.93M -106.60% | -47.66M -- |
Basic EPS | -0.19 -- | -- -- | -- -- | -- -- | -0.07 +63.16% | -0.05 -- | -0.08 -- | -0.12 -- | -0.26 -271.43% | -0.22 -340.00% | -0.18 -125.00% | -0.2 -66.67% | -0.18 +30.77% | -1.1 -400.00% | -1.06 -488.89% | -0.17 +15.00% | -0.98 -444.44% | -0.94 +14.55% | -0.75 +29.25% | -0.68 -300.00% | -0.73 +25.51% | -0.66 +29.79% | -0.65 +13.33% | -0.17 +75.00% | -0.15 +79.45% | -0.11 +83.33% | -0.13 +80.00% | -0.56 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.75 -- | -- -- | -0.73 -- | -0.66 -- | -0.65 +13.33% | -- -- | -0.15 +79.45% | -0.11 +83.33% | -0.13 +80.00% | -- -- |
Diluted EPS | -0.19 -- | -- -- | -- -- | -- -- | -0.07 +63.16% | -0.05 -- | -0.08 -- | -- -- | -0.26 -271.43% | -0.22 -340.00% | -0.18 -125.00% | -- -- | -0.18 +30.77% | -1.1 -400.00% | -1.06 -488.89% | -- -- | -0.98 -444.44% | -0.94 +14.55% | -0.75 +29.25% | -- -- | -0.73 +25.51% | -0.66 +29.79% | -0.65 +13.33% | -- -- | -0.15 +79.45% | -0.11 +83.33% | -0.13 +80.00% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.75 -- | -- -- | -0.73 -- | -0.66 -- | -0.65 +13.33% | -- -- | -0.15 +79.45% | -0.11 +83.33% | -0.13 +80.00% | -- -- |
You can ask Aime
What guidance did Inhibikase's management provide for the next earnings period?What is the revenue and EPS growth rate for Inhibikase year over year?What were the key takeaways from Inhibikase's earnings call?What were the key takeaways from Inhibikase’s earnings call?What is Inhibikase's latest dividend and current dividend yield?What factors drove the changes in Inhibikase's revenue and profit?What does Inhibikase do and what are its main business segments?What is the market's earnings forecast for Inhibikase next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
